Phylogenomic analysis of aquatic and clinical OXA-23-positive Acinetobacter baumannii belonging to the international clone 5 (ST79) from Southeast Brazil

Autor(es):Mostrar menos -

Martins-Goncalves, Thais ; Sano, Elder ; Melocco, Gregory ; Dantas, Karine ; Esposito, Fernanda ; Becerra, Johana ; Fontana, Herrison ; Queiroga, Gustavo ; Pariona, Jesus G. M. ; Cayo, Rodrigo ; Gales, Ana C. ; Sato, Maria I. Z. ; Lincopan, Nilton

• Tipo de documento: Artigo Científico
• Fonte: ONE HEALTH; v. 21, p. 7-pg., 2025-12-01.

Resumo

Categorized as a critical priority pathogen by the World Health Organization (WHO), carbapenem-resistant Acinetobacter baumannii (CRAB) is a leading cause of healthcare-associated infections (HAIs) worldwide. Although the environmental spread of healthcare-acquired A. baumannii strains through hospital wastewater and urban sewage has been suggested, evidence from genomic studies is still lacking. In this study, as part of the Grand Challenges Explorations: New Approaches to Characterize the Global Burden of Antimicrobial Resistance Program, we present genomic data supporting the expansion of international clone IC5/ST79 (Pasteur) to an anthropogenically impacted urban river in Brazil. The environmental OXA-23-producing A. baumannii Ab120 strain conserved a broad resistome to clinically important antimicrobials and carried efflux pump genes associated with tolerance to disinfectants. On the other hand, a wide virulome associated with colonization, evasion of the immune system, as well as survival and persistence in distinct environments was predicted. Noteworthy, a comparative phylogenomic analysis of the environmental Ab120 strain provided evidence that indicates its nosocomial origin and genomic relationship with human-derived OXA-23-positive clinical strains isolated between 2010 and 2017 in Brazil. Our genomic findings suggest adaptation of OXA-23-producing CRAB ST79 beyond hospital settings into non-clinical environments, which is a critical issue deserving active surveillance, particularly in Pan-American countries with a currently endemic clinical status. (AU)

• Processo FAPESP: 19/15578-4 - Viruloma e patogenicidade de linhagens bacterianas prioritárias em saúde única resistentes a carbapenêmicos e polimixinas
• Beneficiário: Fernanda Ribeiro dos Santos Esposito
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 20/08224-9 - One Health Brazilian Resistance (OneBR): base genômica integrada para vigilância, diagnóstico e tratamento da resistência aos antimicrobianos na interface humana-ambiente-animal, no Brasil
• Beneficiário: Nilton Erbet Lincopan Huenuman
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 24/20180-8 - WildBR: plataforma para vigilância epidemiológica e genômica da resistência bacteriana e fúngica na fauna silvestre brasileira
• Beneficiário: Thais Martins Gonçalves
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 23/18292-0 - BiocinBR: Plataforma de pesquisa em bacteriocinas para combater patógenos resistentes a antimicrobianos de prioridade crítica no Brasil
• Beneficiário: Zuleyma Johana Becerra Tellez
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 24/07885-2 - EccBR: Vigilância genômica do complexo Enterobacter cloacae em Saúde Única para controle, diagnóstico e manejo da resistência aos antimicrobianos no Brasil
• Beneficiário: Karine Sousa Dantas
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 21/10599-3 - Instituto Paulista de Resistência aos Antimicrobianos (Projeto ARIES)
• Beneficiário: Arnaldo Lopes Colombo
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs